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Bio-Medical
BHA and BHT are well-known food
preservatives that are excellent radical
scavengers. These compounds, attached
to single-walled carbon nanotubes
(SWNTs), could serve as excellent radi-
cal traps. The amino-BHT groups can
be associated with SWNTs that have car-
bolyxic acid groups via acid-base associ-
ation or via covalent association.
The material can be used as a means
of radiation protection or cellular stress
mitigation via a sequence of quenching
radical species using nano-engineered
scaffolds of SWNTs and their deriva-
tives. It works by reducing the number
of free radicals within or nearby a cell,
tissue, organ, or living organism. This
reduces the risk of damage to DNA and
other cellular components that can
lead to chronic and/or acute patholo-
gies, including (but not limited to) can-
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This technology can be used in clinical oncology and in nuclear disaster response.
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Three innovations address the needs
of the medical world with regard to mi-
crofluidic manipulation and testing of
physiological samples in ways that can
benefit point-of-care needs for patients
such as premature infants, for which
drawing of blood for continuous tests
can be life-threatening in their own
right, and for expedited results. A chip
with sample injection elements, reser-
voirs (and waste), droplet formation
structures, fluidic pathways, mixing
areas, and optical detection sites, was
fabricated to test the various compo-
nents of the microfluidic platform, both
individually and in integrated fashion.
The droplet control system permits a
user to control droplet microactuator
system functions, such as droplet opera-
tions and detector operations. Also, the
programming system allows a user to de-
velop software routines for controlling
droplet microactuator system functions,
such as droplet operations and detector
operations.
A chip is incorporated into the system
with a controller, a detector, input and
output devices, and software. A novel
filler fluid formulation is used for the
transport of droplets with high protein
concentrations. Novel assemblies for de-
tection of photons from an on-chip
droplet are present, as well as novel sys-
tems for conducting various assays, such
as immunoassays and PCR (polymerase
chain reaction).
The lab-on-a-chip (a.k.a., lab-on-a-
printed-circuit board) processes physio-
logical samples and comprises a system
for automated, multi-analyte measure-
ments using sub-microliter samples of
human serum. The invention also re-
lates to a diagnostic chip and system in-
cluding the chip that performs many of
the routine operations of a central lab-
based chemistry analyzer, integrating,
for example, colorimetric assays (e.g.,
for proteins), chemiluminescence/fluo-
rescence assays (e.g., for enzymes, elec-
trolytes, and gases), and/or conducto-
metric assays (e.g., for hematocrit on
plasma and whole blood) on a single
chip platform.
Microfluidic control is essential for a
successful lab-on-a-chip. This innovation
is capable of analysis of bodily fluids
such as blood, sweat, tears, serum,
plasma, cerebrospinal fluid, sweat, and
urine. It can be configured as a mobile
or handheld instrument for use at bed-
side, ICU (intensive care unit), ER
(emergency room), operating rooms,
clinics, or in the field. Alternatively, it
can be configured as a benchtop system.
The chip can be configured to perform
on-chip all-electrical micropumping;
i.e., the chip can be configured to oper-
ate with no off-chip pressure sources or
syringe pumps. Additionally, it can per-
form many simultaneous, parallel opera-
tions on nanodroplets, thereby expedit-
ing production of results. 
To aid in processing the microfluidic
samples, an improved design for loading
a droplet actuator includes a top substrate
that combines glass with one or more
other materials that are easier to manu-
facture. Examples of such materials in-
clude resins and plastics. The glass-plate
portion covers the droplet operations
area of the droplet actuator, providing a
flat, smooth surface for facilitating effec-
tive droplet operations. The plastic por-
tion has one or more openings that pro-
vide a fluid path, from an exterior well,
into the gap of the droplet actuator. The
substrates are associated with electrodes
for conducting droplet operations such as
droplet transport and droplet dispensing.
This work was done by Michael G. Pollack,
Vijay Srinivasan, Allen Eckhardt, Philip Y.
Paik, Arjun Sudarsan, Alex Shenderov, Zhis-
han Hua, and Vamsee K. Pamula of Advanced
Liquid Logic, Inc. for Johnson Space Center. For
further information, contact the JSC Innovation
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Refer to MSC-24283-1/553-1/4-1, volume
and number of this Medical Design Briefs
issue, and the page number.
Digital Microfluidics Sample Analyzer
Combined innovations enable portable analyzers for medical diagnostics, bioterrorism pathogen
detection, and food supply analysis.
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cer, cardiovascular disease, immuno-
suppression, and disorders of the cen-
tral nervous system. These derivatives
can show an unusually high scavenging
ability, which could prove efficacious in
protecting living systems from radical-
induced decay.
This technique could be used to pro-
tect healthy cells in a living biological sys-
tem from the effects of radiation therapy.
It could also be used as a prophylactic or
antidote for radiation exposure due to
accidental, terrorist, or wartime use of ra-
diation-containing weapons; high-alti-
tude or space travel (where radiation ex-
posure is generally higher than desired);
or in any scenario where exposure to ra-
diation is expected or anticipated.
This invention’s ultimate use will be
dependent on the utility in an overall bi-
ological system where many levels of tox-
icity have to be evaluated. This can only
be assessed at a later stage. In vitro toxic-
ity will first be assessed, followed by in
vivo non-mammalian screening in zebra
fish for toxicity and therapeutic efficacy.
This work was done by Jodie L. Conyers,
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the University of Texas Health Science Center
at Houston for Johnson Space Center. For fur-
ther information, contact the JSC Innovation
Partnerships Office at (281) 483-3809. 
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The combination of ethidium mono -
azide (EMA) and post-fragmentation, ran-
domly primed DNA amplification tech-
nologies will enhance the analytical
capability to discern viable from non-viable
bacterial cells in spacecraft-related sam-
ples. Intercalating agents have been widely
used since the inception of molecular biol-
ogy to stain and visualize nucleic acids.
Only recently, intercalating agents such as
EMA have been exploited to selectively dis-
tinguish viable from dead bacterial cells. 
Intercalating dyes can only penetrate
the membranes of dead cells. Once
through the membrane and actually in-
side the cell, they intercalate DNA and,
upon photolysis with visible light, pro-
duce stable DNA monoadducts. Once
the DNA is crosslinked, it becomes in-
soluble and unable to be fragmented
for post-fragmentation, randomly
primed DNA library formation. Viable
organisms’ DNA remains unaffected by
the intercalating agents, allowing for
amplification via post-fragmentation,
randomly primed technologies. This re-
sults in the ability to carry out down-
stream nucleic acid-based analyses on vi-
able microbes to the exclusion of all
non-viable cells. 
This work was done by Myron T. La Duc,
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